11-01 :: December 2010 / January 2011

nanotimes

Companies Facts

expected, initially, to have the capacity to produ- ce around 25kg of cadmium-free quantum dots (CFQD™) annually.

Commercial-scale batches of high quality red CFQD™ have been successfully manufactured during commissioning. Nanoco is now trialling batches for a specific customer application and expects to be able to deliver 1kg of red CFQD™ to the customer within the next few months. Once validated by the custo- mer, this will, subject to the Company’s satisfaction of certain other contractual terms and conditions, trigger a $2m milestone payment. The Company also anticipates shipping 1kg of green CFQD™ in mid 2011, subject to similar terms and conditions.

Furthermore, Nanoco Group announced the comple- tion of a total of 16,700,000 new ordinary shares in the capital of Nanoco. The shares have been placed with institutions at a price of 89 pence per Placing Share. Based on the Placing Price, the gross proceeds of the Placing will be approximately £15 million ($24 million). http://www.nanocogroup.com/

T

he German manufacturer of high-precision optical 3D surface analysis tools NanoFocus AG

(Frankfurt: N2F) starts the product development of a new sensor generation with a major contract from the medical technology industry. The optical sensors in the high end segment will become part of a new product family implementing most recent, state-of- the-art technology.

The order is one milestone of a long-term roadmap with high revenue potential for NanoFocus. The bulk order for the medical sensor provides alongside the

recent capital increase a stable foundation for finan- cing further product development and other projects within this area.

“This is a big step towards series production,” says Jürgen Valentin, Managing Board Technology of NanoFocus AG. http://www.nanofocus.info

N

anogate AG (ISIN DE000A0JKHC9), Germany, has initiated a strategic partnership with Kapy-

fract AG, a major player in Europe’s tunnel fireproo- fing industry. The objective of the partnership is to internationally market and implement innovative coating solutions for traffic tunnels based on Nano- gate-Technologie®

33

. Together, the two companies will

tap the significant market potential available Euro- pean-wide and offer customers a one-stop shop for premium-quality products and services for coating concrete. In recent months, with this in mind, Nano- gate has considerably ramped up its product experti- se and given Kapyfract access to this know-how. The first joint systems are now available by the name of KapyCoat E+. http://www.nanogate.de

N

anoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and

identification of microorganisms, announced the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the Uni- versity of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publica- tion of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS